Keyword: Casma Therapeutics
Martin Williams is now CEO of Caraway Therapeutics, a biotech aiming at the cell’s garbage disposal to treat neurodegenerative diseases.
The public markets have been receptive to early-stage biotechs but will the IPO remain open? We asked our Fierce 15 winners what they thought.
After a couple of years’ incubation at Third Rock, Casma Therapeutics launched in May 2018 with $58.5 million to create treatments aimed at autophagy, or the cell’s garbage disposal.